ライフサイエンスコーパス: proarrhythmia

1 nonfailing hearts and absence of ventricular proarrhythmia.

2 g to increased conduction in homogeneity and proarrhythmia.

3 titute an important mechanism of ventricular proarrhythmia.

4 e device longevity, and avoid device-induced proarrhythmia.

5 of non-PV foci are sufficient to treat this proarrhythmia.

6 ac abnormalities secondary to a high risk of proarrhythmia.

7 hythm disorders with an acceptable degree of proarrhythmia.

8 and should minimize the risk of ventricular proarrhythmia.

9 en withdrawn for their ability to cause such proarrhythmia.

10 antiarrhythmic drugs carries a high risk for proarrhythmias.

11 l mechanism for individual susceptibility to proarrhythmia and highlight the need for a new paradigm

12 stigate the relationship between CRT-induced proarrhythmia and LV lead location within scar.

13 en mainly by hospitalizations for arrhythmia/proarrhythmia and other cardiovascular causes, but not b

14 However, the lack of proarrhythmia and the reduction in arrhythmic death supp

15 clinical consequences-arrhythmia recurrence, proarrhythmia, and death-that have now been reported in

16 s under which adverse event rates, including proarrhythmia, are expectedly low, would favor outpatien

17 The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons fro

18 The CiPA (Comprehensive in vitro Proarrhythmia Assay) proposes to overcome these limitati

19 RVP may have ventricular proarrhythmia because of competition of paced and intrin

20 infection, unnecessary shocks, potential for proarrhythmia, device malfunction, highly publicized man

21 The occurrence of proarrhythmia did not correlate with ibutilide plasma co

22 scar was significantly more frequent in the proarrhythmia group (60% versus 9% P=0.03 on epicardial

23 Ventricular proarrhythmia hinders pharmacological atrial fibrillatio

24 DZX-mediated proarrhythmia in T2DM was not related to changes in the

25 The risk of proarrhythmia is increased in patients with abnormal car

26 erter-defibrillators (ICDs), but ventricular proarrhythmia is less clear.

27 ng from intermittent inappropriate pacing to proarrhythmia leading to patient mortality.

28 review some methodologies employed to assess proarrhythmia liability of drugs, discuss the challenges

29 ized and/or excreted are the cornerstones of proarrhythmia management.

30 s associated with QT prolongation yet absent proarrhythmia markers for Torsade de Pointes (TdP).

31 rapamil, vanoxerine and bepridil produced no proarrhythmia markers.

32 tioned, particularly for sotalol, with which proarrhythmia may be dose related.

33 disease, for patients receiving a drug whose proarrhythmia may be idiosyncratic (e.g., quinidine), an

34 e the potential mechanism for the flecainide proarrhythmia observed in CAST, the voltage dependence o

35 There was no ventricular proarrhythmia observed throughout the course of this stu

36 CRT-induced proarrhythmia occurred in 8 patients (12.5%).

37 No proarrhythmia occurred.

38 lying appropriate medical management without proarrhythmia or compromised ICD function.

39 No proarrhythmia or other negative effects were discernable

40 l storm (100% versus 39% of patients with no proarrhythmia; P<0.01), requiring temporary biventricula

41 CRT-induced proarrhythmia presented early with electrical storm and

42 diac resynchronization therapy (CRT)-induced proarrhythmia remains unknown.

43 All ventricular proarrhythmia resulted from shocks delivered during the

44 on mechanisms underlying QT prolongation and proarrhythmia, risk factors, including the role of genet

45 The current proarrhythmia safety testing paradigm, although highly e

46 tial mechanistic basis for the novel form of proarrhythmia seen with this macrolide antibiotic.

47 pecific fashion, and the risk of ventricular proarrhythmia should be minimized.

48 In a model of proarrhythmia, the dog with chronic atrioventricular blo

49 ses the new concepts of arrhythmogenesis and proarrhythmia; the long QT interval syndrome; newer, mor

50 ocyte action potentials, AF, and ventricular proarrhythmia, to determine the relationship between the

51 No proarrhythmia was observed and arrhythmia termination ca

52 A low incidence of serious proarrhythmia was seen with the administration of ibutil

53 No significant proarrhythmias were noted.

54 dy provides mechanistic insights into atrial proarrhythmia with SQT3 Kir2.1 mutations and highlights